Drug Profile
Research programme: infectious disease therapeutics - Visterra
Alternative Names: Monoclonal antibody therapeutics - Visterra; VIS-FLX; VIS-FNG; VIS-RSVLatest Information Update: 28 Dec 2023
Price :
$50
*
At a glance
- Originator Visterra
- Class Anti-infectives; Antivirals; Bispecific antibodies; Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Influenza A virus infections; Mycoses; Respiratory syncytial virus infections
Most Recent Events
- 28 Dec 2023 No recent reports of development identified for preclinical development in Influenza-A-virus-infections(Prevention) in USA (Parenteral)
- 28 Dec 2023 No recent reports of development identified for preclinical development in Mycoses in USA (Parenteral)
- 28 Dec 2023 No recent reports of development identified for preclinical development in Respiratory-syncytial-virus-infections in USA (Parenteral)